JP2016538269A - 筋ジストロフィーの処置のための方法 - Google Patents

筋ジストロフィーの処置のための方法 Download PDF

Info

Publication number
JP2016538269A
JP2016538269A JP2016526156A JP2016526156A JP2016538269A JP 2016538269 A JP2016538269 A JP 2016538269A JP 2016526156 A JP2016526156 A JP 2016526156A JP 2016526156 A JP2016526156 A JP 2016526156A JP 2016538269 A JP2016538269 A JP 2016538269A
Authority
JP
Japan
Prior art keywords
compound
subject
pharmaceutically acceptable
acceptable salt
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016526156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538269A5 (enExample
Inventor
アーネスト ディー． ブッシュ，
アーネスト ディー． ブッシュ，
フランソワ ニック，
フランソワ ニック，
キャサリン イェーガーシュミット，
キャサリン イェーガーシュミット，
フローレンス シルビー ナムール，
フローレンス シルビー ナムール，
ローランド ブランク，
ローランド ブランク，
ジャン−ミカエル ルフランソワ，
ジャン−ミカエル ルフランソワ，
クリストフ ペソト，
クリストフ ペソト，
ピエール ドゥプレ，
ピエール ドゥプレ，
ニコラス トリバーユ，
ニコラス トリバーユ，
ピエト トム バート ポール ウィゲリンク，
ピエト トム バート ポール ウィゲリンク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016538269A publication Critical patent/JP2016538269A/ja
Publication of JP2016538269A5 publication Critical patent/JP2016538269A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016526156A 2013-10-25 2014-10-24 筋ジストロフィーの処置のための方法 Pending JP2016538269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895832P 2013-10-25 2013-10-25
US61/895,832 2013-10-25
PCT/US2014/062178 WO2015061685A1 (en) 2013-10-25 2014-10-24 Methods for treatment of muscular dystrophies

Publications (2)

Publication Number Publication Date
JP2016538269A true JP2016538269A (ja) 2016-12-08
JP2016538269A5 JP2016538269A5 (enExample) 2017-12-07

Family

ID=52993619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526156A Pending JP2016538269A (ja) 2013-10-25 2014-10-24 筋ジストロフィーの処置のための方法

Country Status (9)

Country Link
US (2) US20160250188A1 (enExample)
EP (1) EP3060206A4 (enExample)
JP (1) JP2016538269A (enExample)
CN (1) CN105979943A (enExample)
AU (1) AU2014339917A1 (enExample)
BR (1) BR112016009214A8 (enExample)
CA (1) CA2928235A1 (enExample)
MX (1) MX2016005287A (enExample)
WO (1) WO2015061685A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
WO2018156801A2 (en) * 2017-02-22 2018-08-30 Bioincept, Llc Peptides and methods of treating dystrophy-related disorders using the same
WO2019236677A1 (en) * 2018-06-05 2019-12-12 The Regents Of The University Of California Methods for treating muscular dystrophies
EP3952849B1 (en) 2019-04-12 2024-09-18 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535709A (ja) * 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィー治療のための医薬組合せ剤
JP2012524708A (ja) * 2008-09-11 2012-10-18 ガラパゴス・ナムローゼ・フェンノートシャップ アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20090078A1 (it) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535709A (ja) * 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィー治療のための医薬組合せ剤
JP2012524708A (ja) * 2008-09-11 2012-10-18 ガラパゴス・ナムローゼ・フェンノートシャップ アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, JPN6019026368, 2012, pages 8236 - 8247, ISSN: 0004224497 *
PHARMACOLOGICAL RESEARCH, vol. 72, JPN6018030342, June 2013 (2013-06-01), pages 9 - 24, ISSN: 0004224496 *

Also Published As

Publication number Publication date
WO2015061685A1 (en) 2015-04-30
US20190167640A1 (en) 2019-06-06
US20160250188A1 (en) 2016-09-01
CN105979943A (zh) 2016-09-28
AU2014339917A1 (en) 2016-05-12
EP3060206A1 (en) 2016-08-31
MX2016005287A (es) 2017-02-22
CA2928235A1 (en) 2015-04-30
EP3060206A4 (en) 2017-04-19
BR112016009214A8 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
CN114929209A (zh) 肌萎缩侧索硬化的治疗
Bertini et al. 134th ENMC international workshop: outcome measures and treatment of spinal muscular Atrophy11–13 february 2005Naarden, The Netherlands
Pozzo-Miller et al. Rett syndrome: reaching for clinical trials
EP3043789B1 (en) Use of a ppar-delta agonists for treating muscle atrophy
AU2018219861B2 (en) Methods of treating seizure disorders and prader-willi syndrome
US20210252023A1 (en) Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US20190167640A1 (en) Methods for treatment of muscular dystrophies
JP2022543242A (ja) ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法
EP3989962A1 (en) Combination therapy with acetyl-leucine and miglustat
Reilly et al. 136th ENMC International Workshop: Charcot–Marie–Tooth disease type 1A (CMT1A) 8–10 April 2005, Naarden, The Netherlands
Arora Duchenne muscular dystrophy: Still an incurable disease
KR20200146038A (ko) 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물
US10195165B2 (en) Methods of treating Prader-Willi syndrome
McDonald Neuromuscular diseases
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
Syed et al. Muscular Dystrophy: Underlying Cellular and Molecular Mechanisms and Various Nanotherapeutic Approaches for Muscular Dystrophy
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Goemans et al. Therapy development and clinical outcome measures for Duchenne muscular dystrophy
Maricelli Phenotypic Characterization and Treatment of a Novel Mouse Model for Limb-Girdle Muscular Dystrophy 2i
Inns Exploring mechanisms of disuse atrophy and optimal rehabilitation strategies for the restoration of muscle mass, structure & function
Kölbel et al. METABOLIC MYOPATHIES II: P. 355Glycogen storage disease type IV: a wide clinical range of neuromuscular phenotypes
Wenninger et al. METABOLIC MYOPATHIES II: P. 354Safety and efficacy of recurrent inspiratory muscle training in late onset Pompe disease
Decostre et al. METABOLIC MYOPATHIES II: P. 356Lower limb muscle strength and function in a cross-sectional study of patients with glycogen storage disease type IIIa
Gatheridge Duchenne muscular dystrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303